关键词:
5,4'-dihydroxyflavone
baicalein
gestational diabetes mellitus
liquiritigenin
neoliquiritin
Polygonati Rhizoma
摘要:
Objective To explore the components and mechanism of Polygonati Rhizoma in treatment of gestational diabetes mellitus by network pharmacology and molecular docking. Methods The active components of Polygonati Rhizoma were screened through the TCMSP, TCMIP, and BATMAN-TCM database, and the potential targets of the active components were screened through the Swiss Target Prediction database. The disease targets of gestational diabetes mellitus were retrieved through GeneCards, DisGeNET, and OMIM. The Venny 2.1 software was used to draw a Venn diagram to obtain the common targets. The STRING database was used to draw the PPI of the intersection targets, and the Cytoscape 3.10.0 software was used to screen the key targets. The Weishengxin online platform was used for GO function and KEGG enrichment analysis. The “drug–component–target–pathway–disease” network diagram was constructed using Cytoscape 3.10.0 and topological analysis was performed. Molecular docking was performed using AutoDock Vina software, and the results were visualized using Pymol 2.4 software. Results 22 Active components of Polygonati Rhizoma and 102 common targets of Polygonati Rhizoma and gestational diabetes mellitus were obtained. The main components of Polygonati Rhizoma in treatment of gestational diabetes mellitus were 5,4'-dihydroxyflavone, baicalein, neoliquiritin, and liquiritigenin, which act on the core targets EGFR, PPARG, ESR1, and PTGS2, regulated the PI3K/Akt signaling pathway, AMPK signaling pathway and other pathways plays a role in treatment of gestational diabetes mellitus. The molecular docking results showed that the active components of Polygonati Rhizoma, 5,4'-dihydroxyflavone, baicalein, neoliquiritin, and liquiritigenin had good binding ability with the key targets EGFR, PPARG, ESR1, and PTGS2. Conclusion Polygonati Rhizoma mainly treats gestational diabetes mellitus by acting on PTGS2, PPARG, ESR1, EGFR targets, and regulating PI3K/Akt signaling pathway, AMPK signaling path